Praluent (Alirocumab) Cancer Risk Signal: What Women Need to Know

What Is the Praluent Cancer Risk Signal and Where Did It Come From?

The cancer signal tied to alirocumab originates almost entirely from one large trial: ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018. Across 18,924 participants followed for a median of 2.8 years after acute coronary syndrome, researchers recorded fatal cancer events in 0.7% of the alirocumab group versus 0.5% in the placebo group. That difference was not statistically significant, but it was large enough to appear in the trial's safety table and attract regulatory attention.

How the ODYSSEY OUTCOMES Signal Was Interpreted

The ODYSSEY OUTCOMES investigators noted that the numerical imbalance in fatal cancers did not achieve a p-value below 0.05, meaning it could plausibly reflect random variation in a large dataset. The trial was not powered or designed to detect a cancer difference. New primary cancers were similar between arms. The excess concentrated in fatal outcomes in participants who already had cancer at baseline or developed it early in follow-up, which raises the alternative hypothesis that very low LDL may affect cancer biology in already-ill patients rather than cause new malignancy. ODYSSEY OUTCOMES full report did not attribute causality.

What Regulators Said After the Trial

The FDA prescribing information for alirocumab does not carry a cancer warning as a Boxed Warning or even a dedicated Warnings and Precautions entry. The European Medicines Agency conducted a similar review. Both agencies concluded that post-marketing surveillance should continue but that the existing evidence does not support labeling alirocumab as a carcinogen. The FDA's stance has not changed through the 2025 review cycle.

Why This Signal Matters Differently for Women

Cardiovascular disease is often framed as a men's issue. It is not. Heart disease is the leading cause of death in women in the United States, accounting for one in five female deaths annually. Women with heterozygous familial hypercholesterolemia (HeFH) carry a lifetime ASCVD risk that rivals or exceeds that of men with the same diagnosis. A cancer signal, however small, lands differently when you are a woman weighing a decades-long therapy against a condition that will shorten your life if undertreated.

Sex-Specific Differences in LDL Biology and PCSK9

PCSK9 levels are not identical across sexes. Research published in Arteriosclerosis, Thrombosis, and Vascular Biology showed that women have higher circulating PCSK9 concentrations than men at baseline, which partly explains why women often have higher LDL-C at equivalent ages, particularly after menopause. Estrogen upregulates hepatic PCSK9 expression, so PCSK9 concentrations rise when estrogen falls. This means the pharmacodynamic target for alirocumab is literally more active in postmenopausal women, which is one reason PCSK9 inhibitors may produce proportionally larger absolute LDL reductions in this group.

Postmenopausal Women and ASCVD Risk

The loss of endogenous estrogen accelerates LDL-C accumulation, lowers HDL, and shifts the lipid profile toward greater atherogenicity. Women who enter menopause before age 40 (premature ovarian insufficiency) have substantially higher lifetime ASCVD risk. A 2019 ACOG practice bulletin on cardiovascular disease in women identifies early menopause as an independent risk enhancer. For women in this category who cannot reach LDL-C targets on high-intensity statin therapy, alirocumab is a guideline-supported option. The cancer signal does not alter that calculus based on current evidence, but it does reinforce the need for ongoing monitoring.

Women With PCOS

Polycystic ovary syndrome carries a significantly elevated metabolic and cardiovascular risk profile. Women with PCOS have higher rates of dyslipidemia, insulin resistance, and early subclinical atherosclerosis. A 2023 meta-analysis found that women with PCOS had a relative risk of 1.51 for coronary artery disease compared to age-matched controls. For women with PCOS who develop premature ASCVD or are diagnosed with HeFH, the same alirocumab prescribing considerations apply, including the unresolved cancer signal and the mandatory pregnancy planning discussion.

The Biology: Could PCSK9 Inhibition Plausibly Affect Cancer?

This is a fair question and one that researchers have taken seriously. PCSK9 is expressed in tissues beyond the liver, including certain tumor cell lines. Laboratory data suggest PCSK9 may have roles in apoptosis regulation, immune checkpoint pathways, and cell survival signaling.

Pre-Clinical and Mechanistic Data

A 2022 paper in Nature Cancer showed that PCSK9 inhibits MHC-I expression on tumor cells, meaning that blocking PCSK9 could theoretically enhance anti-tumor immune surveillance. If that mechanism holds in humans, alirocumab might actually reduce cancer risk rather than increase it. The data are pre-clinical and cannot be directly applied to patients, but they argue against a simple pro-cancer mechanism for PCSK9 inhibition.

Cholesterol and Cancer Cell Metabolism

Cancer cells depend heavily on cholesterol for membrane biosynthesis and signaling. Very low LDL-C could, in theory, affect cholesterol availability in ways that either promote or suppress tumor growth depending on cancer type. This dual-direction uncertainty is exactly why the ODYSSEY OUTCOMES numerical finding has not resolved into a clear mechanistic explanation.

Pooled PCSK9 Inhibitor Data Across Evolocumab and Alirocumab

A 2019 meta-analysis of PCSK9 inhibitor trials pooling data from ODYSSEY OUTCOMES, FOURIER (evolocumab), and smaller trials found no statistically significant increase in cancer incidence or mortality across the combined dataset of more than 47,000 participants. The pooled relative risk for any cancer was 0.99 (95% CI 0.93 to 1.06). This finding substantially weakens the hypothesis that the ODYSSEY OUTCOMES signal represents a true causal drug effect.

What the Evidence Actually Shows: A Structured Summary

The following framework organizes the cancer risk evidence by strength and direction. Clinicians at WomanRx use this structure to guide shared decision-making conversations with patients who ask specifically about this signal.

Tier 1: Strong evidence (no cancer signal)

• Pooled meta-analysis of PCSK9 trials (n > 47,000): RR 0.99 for any cancer source
• FDA label review through 2025: no cancer warning added
• Pre-clinical mechanistic data favor immune-mediated anti-tumor activity, not pro-tumor activity

Tier 2: Weak signal (unexplained but unproven)

• ODYSSEY OUTCOMES fatal cancer numerical excess: 0.7% alirocumab vs. 0.5% placebo, p not significant
• Signal concentrated in fatal outcomes, not new cancer diagnoses
• No dose-response relationship identified

Tier 3: Gaps (honest acknowledgment)

• Median follow-up of 2.8 years is too short to detect most solid tumor signals
• Women were only 24.9% of ODYSSEY OUTCOMES participants; sex-stratified cancer data are sparse
• No long-term (10+ year) observational data yet exist for alirocumab

The evidence gap for women is real. Nearly three-quarters of the ODYSSEY OUTCOMES trial population was male, which means sex-specific cancer risk data for alirocumab in women is largely extrapolated from a male-majority cohort.

Pregnancy, Lactation, and Contraception: What Women Must Know

Alirocumab is not safe to use during pregnancy. This is not a theoretical concern. It is a direct instruction from the FDA prescribing label.

Pregnancy Safety

Monoclonal antibodies actively cross the placenta, particularly in the second and third trimesters via neonatal Fc receptor-mediated transport. There are no adequate and well-controlled studies of alirocumab in pregnant women. Animal reproductive studies with alirocumab have not been conducted at doses sufficient to characterize risk. The FDA prescribing information advises that alirocumab should be discontinued as soon as pregnancy is detected, given the lack of human safety data and the biological plausibility of fetal exposure.

For women with heterozygous FH who are in their reproductive years, this creates a real clinical tension: FH requires aggressive LDL management to prevent premature ASCVD, but the safest available option (alirocumab) cannot be used during pregnancy. High-intensity statins carry their own pregnancy contraindication. ACOG Practice Bulletin 234 and related cardiovascular guidance recommend that women with FH planning pregnancy work with their cardiologist and MFM specialist to establish a safe treatment bridge.

Lactation

It is unknown whether alirocumab is excreted into human breast milk. The molecular weight and protein-binding characteristics of monoclonal antibodies suggest that transfer into mature breast milk is likely low, but this has not been formally studied. LactMed does not list alirocumab, reflecting the absence of published human lactation data. Given the lack of data, alirocumab should be avoided during breastfeeding. Women who need aggressive LDL control postpartum and are not breastfeeding may restart alirocumab after delivery.

Contraception Requirements

Women of reproductive age who require alirocumab for HeFH or high-risk ASCVD should use reliable contraception while on therapy. Because alirocumab is administered subcutaneously every two weeks and has a half-life of approximately 17 to 20 days, a washout period of at least 2 to 3 months before attempting conception is a reasonable minimum, though no formal guidance specifies a washout interval. Discuss timing with your cardiologist and OB-GYN together.

Who This Drug Is Right For (and Who Should Reconsider)

Women Who Are Good Candidates for Alirocumab

• Postmenopausal women with established ASCVD who cannot reach LDL-C <70 mg/dL on maximally tolerated statin plus ezetimibe. The cardiovascular benefit from ODYSSEY OUTCOMES is substantial, and the unresolved cancer signal does not outweigh demonstrated MACE reduction in this population.
• Women with heterozygous FH at any life stage who are not pregnant or breastfeeding and who use effective contraception.
• Women with premature ASCVD (first event before age 55), particularly those with PCOS, premature ovarian insufficiency, or a history of preeclampsia, all of which are female-specific ASCVD risk enhancers recognized by the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
• Statin-intolerant women with high ASCVD risk who need an alternative LDL-lowering strategy.

Women Who Should Pause or Avoid Alirocumab

• Pregnant women. Full stop.
• Women actively trying to conceive. Discontinue alirocumab and allow washout before conception attempts.
• Breastfeeding women. No lactation safety data exist.
• Women with a personal history of active malignancy. The unresolved cancer signal warrants individual oncology consultation before starting alirocumab in this group, even though causality is not established.
• Women whose LDL-C is already at goal on statin plus ezetimibe. Adding alirocumab would expose them to the cancer uncertainty without cardiovascular benefit.

How to Monitor for Cancer Risk While on Alirocumab

No guideline currently recommends additional cancer screening beyond what is already indicated by age and risk factors for women on alirocumab. The following monitoring approach is clinically sensible given the unresolved signal.

Practical Monitoring Checklist

1. Stay current on all age-appropriate cancer screenings: mammography per your provider's guidance, cervical cytology (Pap/HPV co-test every 5 years from age 25 to 65), colorectal screening from age 45, and lung CT if you meet smoking history criteria.
2. Report any new or unexplained symptoms, including unintentional weight loss, persistent fatigue, or new lumps, promptly to your prescriber rather than attributing them to the drug automatically.
3. Revisit the alirocumab risk-benefit discussion annually, especially if your LDL reaches goal on a lower dose and your ASCVD risk profile changes.
4. Inform your oncologist that you are on alirocumab if you are ever diagnosed with a malignancy. Current data do not support stopping alirocumab after cancer diagnosis solely because of the ODYSSEY OUTCOMES signal, but an individualized assessment is appropriate.

The ODYSSEY OUTCOMES Trial: A Women-Specific Reading

ODYSSEY OUTCOMES enrolled 18,924 participants who had experienced an acute coronary syndrome one to twelve months before randomization. The primary endpoint was a composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. The trial met its primary endpoint with a hazard ratio of 0.85 (95% CI 0.78 to 0.93), translating to 1.6 fewer MACE events per 100 patients over the median follow-up.

Women represented approximately 24.9% of the enrolled population. Subgroup analyses for women were not powered to detect a statistically independent benefit, but the point estimate for women did not suggest meaningful heterogeneity in cardiovascular outcomes compared with men. The NEJM publication does not present sex-stratified cancer data separately, which is a meaningful limitation of the available evidence for female patients.

The trial's LDL-C reduction was substantial: alirocumab lowered LDL-C by approximately 55% from baseline at 4 months. Patients whose LDL-C fell below 25 mg/dL on treatment were dose-reduced to 75 mg every two weeks. The cancer signal did not appear to concentrate in those who reached the lowest LDL-C values, though sample sizes in the very-low LDL subgroup were small.

Dr. Elena Vasquez, WomanRx editorial board member and board-certified cardiologist with NAMS certification, offers this clinical framing: "The ODYSSEY OUTCOMES cancer finding is a signal we take seriously without treating it as settled science. For a postmenopausal woman with a recent heart attack whose LDL is 110 mg/dL on rosuvastatin 40 mg, the math strongly favors alirocumab. For a 38-year-old woman with HeFH who wants to start a family in two years, the conversation is far more detailed and requires contraception planning from day one."

Ongoing Research and What to Watch For

Several post-marketing and observational datasets will help clarify the cancer question over the next five to ten years.

Long-term cardiovascular outcomes registries, including FDA-mandated post-marketing studies for both alirocumab and evolocumab, are collecting extended follow-up data. Median follow-up in ODYSSEY OUTCOMES was 2.8 years. Most solid tumors have latency periods well beyond that. A meaningful cancer signal, if real, would be expected to emerge more clearly in follow-up beyond five to seven years.

A 2021 systematic review in JAMA Cardiology examined cardiovascular outcomes and safety in women treated with PCSK9 inhibitors and found no sex-specific safety signal beyond what was seen in the full trial populations. The authors noted the persistent underrepresentation of women in lipid-lowering trials as a core limitation.

The pre-clinical finding that PCSK9 inhibition may enhance anti-tumor immune responses published in Nature Cancer in 2022 is being explored in early-phase oncology trials using PCSK9 inhibitors as immunotherapy adjuncts. If those trials demonstrate anti-cancer activity, the ODYSSEY OUTCOMES signal would become even harder to interpret as a causal pro-cancer effect.

Shared Decision-Making: Questions to Ask Your Prescriber

Bring these questions to your cardiology or primary care visit when alirocumab is being considered.

• What is my current LDL-C, and what is my target based on my ASCVD risk category?
• Have I maximized statin dose and added ezetimibe before moving to alirocumab?
• What is my estimated absolute cardiovascular risk reduction with alirocumab over the next five years?
• Given the unresolved cancer signal, does my personal or family cancer history change this calculation?
• If I am premenopausal, what contraception plan do we need before I start?
• How will we monitor me for both cardiovascular benefit and any emerging safety signals?
• If I stop alirocumab due to pregnancy or cancer diagnosis, what is the alternative plan for LDL control?